Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ35AP
|
|||
| Drug Name |
TAK-861
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Narcolepsy type 1 [ICD-11: 7A20.0] | Phase 2 | [1] | |
| Narcolepsy type 2 [ICD-11: 7A20.1] | Phase 2 | [2] | ||
| Company |
Takeda
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Orexin receptor type 2 (HCRTR2) | Target Info | Agonist | [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05687903) A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05687916) A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2). U.S.National Institutes of Health. | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.